BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 15, 2010
 |  BC Week In Review  |  Company News  |  Deals

Active Biotech, Teva deal

Teva will now have exclusive, worldwide rights to develop and commercialize Active Biotech's laquinimod. The companies added the Nordic and Baltic...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >